ES2613177T3 - Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2 - Google Patents

Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2 Download PDF

Info

Publication number
ES2613177T3
ES2613177T3 ES09715322.5T ES09715322T ES2613177T3 ES 2613177 T3 ES2613177 T3 ES 2613177T3 ES 09715322 T ES09715322 T ES 09715322T ES 2613177 T3 ES2613177 T3 ES 2613177T3
Authority
ES
Spain
Prior art keywords
myelination
ggf2
disease
disorder associated
reduced levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09715322.5T
Other languages
English (en)
Spanish (es)
Inventor
Haesun Kim
Anthony O. Caggiano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of ES2613177T3 publication Critical patent/ES2613177T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES09715322.5T 2008-02-29 2009-03-02 Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2 Active ES2613177T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29
US67589P 2008-02-29
PCT/US2009/001356 WO2009108390A2 (en) 2008-02-29 2009-03-02 Method for achieving desired glial growth factor 2 plasma levels

Publications (1)

Publication Number Publication Date
ES2613177T3 true ES2613177T3 (es) 2017-05-23

Family

ID=41016663

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09715322.5T Active ES2613177T3 (es) 2008-02-29 2009-03-02 Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2
ES16182139T Active ES2811127T3 (es) 2008-02-29 2009-03-02 Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16182139T Active ES2811127T3 (es) 2008-02-29 2009-03-02 Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial

Country Status (11)

Country Link
US (5) US8410050B2 (https=)
EP (3) EP3120863B1 (https=)
JP (2) JP5697455B2 (https=)
CN (2) CN104645315A (https=)
AU (1) AU2009217606B2 (https=)
BR (1) BRPI0908271A2 (https=)
CA (1) CA2717193C (https=)
ES (2) ES2613177T3 (https=)
PL (2) PL3120863T3 (https=)
RU (3) RU2530650C2 (https=)
WO (1) WO2009108390A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3120863T3 (pl) 2008-02-29 2021-02-22 Acorda Therapeutics, Inc. Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu
CN102159236A (zh) 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
EP2328606B1 (en) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
WO2011047183A2 (en) 2009-10-14 2011-04-21 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
CN103118698A (zh) * 2010-05-28 2013-05-22 意识-Nrg公司 神经调节素同种型，神经调节素多肽和其使用
WO2012021818A2 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
AU2013237896B2 (en) * 2012-03-30 2017-11-02 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
JP7064197B2 (ja) * 2016-09-23 2022-05-10 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU3003701A (en) 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
US20080213817A1 (en) * 2004-02-19 2008-09-04 Michael Karin Enhancement of Th2-Dependent and Inflammatory Response
JP2008528697A (ja) 2005-02-02 2008-07-31 ネクサスファーマ・インコーポレイテッド 癌の病因に関連するウィルス感染症を治療するためのアミン誘導体含有組成物および方法
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
PL3120863T3 (pl) 2008-02-29 2021-02-22 Acorda Therapeutics, Inc. Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu
CN102834498B (zh) 2010-04-01 2014-04-30 宝洁公司 织物软化剂
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Also Published As

Publication number Publication date
EP2262527B1 (en) 2016-08-03
US9744215B2 (en) 2017-08-29
US9272015B2 (en) 2016-03-01
WO2009108390A2 (en) 2009-09-03
BRPI0908271A2 (pt) 2017-06-13
PL2262527T3 (pl) 2017-07-31
EP3120863B1 (en) 2020-05-06
PL2262527T4 (pl) 2017-07-31
EP2262527A2 (en) 2010-12-22
US20130345131A1 (en) 2013-12-26
WO2009108390A3 (en) 2010-11-18
CN104645315A (zh) 2015-05-27
PL3120863T3 (pl) 2021-02-22
JP5964920B2 (ja) 2016-08-03
RU2014131265A (ru) 2016-02-20
EP3120863A1 (en) 2017-01-25
JP5697455B2 (ja) 2015-04-08
US20210060128A1 (en) 2021-03-04
US8410050B2 (en) 2013-04-02
JP2015042656A (ja) 2015-03-05
RU2019110452A (ru) 2020-10-09
CA2717193C (en) 2022-08-16
ES2811127T3 (es) 2021-03-10
EP3750551A1 (en) 2020-12-16
US20160367634A1 (en) 2016-12-22
AU2009217606B2 (en) 2015-03-05
CN102026651A (zh) 2011-04-20
JP2011513310A (ja) 2011-04-28
AU2009217606A1 (en) 2009-09-03
CA2717193A1 (en) 2009-09-03
US20100029559A1 (en) 2010-02-04
US20180055909A1 (en) 2018-03-01
CN102026651B (zh) 2015-06-03
RU2530650C2 (ru) 2014-10-10
US10675331B2 (en) 2020-06-09
RU2687097C2 (ru) 2019-05-07
RU2010139906A (ru) 2012-04-10

Similar Documents

Publication Publication Date Title
ES2613177T3 (es) Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2
Jelkmann et al. Beneficial and ominous aspects of the pleiotropic action of erythropoietin
Chen et al. Cdc42 participates in the regulation of ADF/cofilin and retinal growth cone filopodia by brain derived neurotrophic factor
Chen et al. Ginkgolide K promotes angiogenesis in a middle cerebral artery occlusion mouse model via activating JAK2/STAT3 pathway
Syed et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine
ES2664394T3 (es) Dosificación terapéutica de una neuregulina o de una subsecuencia de la misma para el tratamiento o la profilaxis de la insuficiencia cardiaca
Yang et al. Neuroprotective effects of VEGF administration after focal cerebral ischemia/reperfusion: dose response and time window
Iaci et al. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke
KR101174333B1 (ko) 심근 경색증의 치료 방법
Luo et al. Multiple roles of apelin/APJ system in eye diseases
AU2017203961B2 (en) Method for achieving desired glial growth factor 2 plasma levels
HK1152230B (en) Compositions for achieving desired glial growth factor 2 plasma levels
Jia Vascular-cognitive impairment after chronic high-thoracic spinal cord injury
Sanchez Molecular characterization of NGF modulation of erbB2 signaling in Schwann cells
Obert Targeting the Tight Junction Protein, Zonula Occludens-1, with the Connexin 43 Mimetic Peptide, Αct-1 Reduces VEGF-Dependent RPE Pathophysiology
EP2049146A2 (en) Use of proteins of the sdf-1-family for for improvement of axonal plasticity or for axonal regeneration following lesions